NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis

Tsimikas, Sotirios; Fazio, Sergio; Ferdinand, Keith C.; Ginsberg, Henry N.; Koschinsky, Marlys L.; Marcovina, Santica M.; Moriarty, Patrick M.; Rader, Daniel J.; Remaley, Alan T.; Soffer, Gissette; Santos, Raul D.; Thanassoulis, George; Witztum, Joseph L.; Danthi, Simhan; Olive, Michelle; Liu, Lijuan

Pathophysiological, epidemiological, and genetic studies provide strong evidence that lipoprotein(a) [Lp(a)] is a causal mediator of cardiovascular disease (CVD) and calcific aortic valve disease (CAVD). Specific therapies to address Lp(a)-mediated CVD and CAVD are in clinical development. Due to knowledge gaps, the National Heart, Lung, and Blood Institute organized a working group that identified challenges in fully understanding the role of Lp(a) in CVD/CAVD. These included the lack of research funding, inadequate experimental models, lack of globally standardized Lp(a) assays, and inadequate understanding of the mechanisms underlying current drug therapies on Lp(a) levels. Specific recommendations were provided to facilitate basic, mechanistic, preclinical, and clinical research on Lp(a); foster collaborative research and resource sharing; leverage expertise of different groups and centers with complementary skills; and use existing National Heart, Lung, and Blood Institute resources. Concerted efforts to understand Lp(a) pathophysiology, together with diagnostic and therapeutic advances, are required to reduce Lp(a)-mediated risk of CVD and CAVD.


  • thumnail for nihms926088_NIH lpa statement.pdf nihms926088_NIH lpa statement.pdf application/pdf 347 KB Download File

Also Published In

Journal of the American College of Cardiology

More About This Work

Academic Units
Published Here
February 10, 2020